Movement Alert｜Definium Therapeutics Rises 5.5% in Regular Trading, DT120 Phase 3 Data and Sector M&A Fuel Momentum

Market Focus07-16

On July 16, Definium Therapeutics rose 5.5% in regular trading, trading at $46.5/share, with turnover of $24.58 million.

On the news front, multiple catalysts continue to support buying momentum. The company previously reported positive topline results from its pivotal Phase 3 EMERGE study of DT120 oral disintegrating tablet for Major Depressive Disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful improvement over placebo. The company subsequently completed an $805 million capital raise with underwriters fully exercising the overallotment option. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.

Adding sector tailwinds, Eli Lilly announced a $3.8 billion acquisition of AtaiBeckley at a 26% premium, deepening its neuroscience pipeline in psychedelic-based treatments. The deal explicitly referenced Definium Therapeutics as a peer developing a promising LSD-based approach for MDD, further validating the therapeutic space and investor interest in the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173601696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173601696","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Definium Therapeutics Rises 5.5% in Regular Trading, DT120 Phase 3 Data and Sector M&A Fuel Momentum","media":"Market Focus","content":"<p><p>On July 16, Definium Therapeutics rose 5.5% in regular trading, trading at $46.5/share, with turnover of $24.58 million.</p><p>On the news front, multiple catalysts continue to support buying momentum. The company previously reported positive topline results from its pivotal Phase 3 EMERGE study of DT120 oral disintegrating tablet for Major Depressive Disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful improvement over placebo. The company subsequently completed an $805 million capital raise with underwriters fully exercising the overallotment option. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.</p><p>Adding sector tailwinds, Eli Lilly announced a $3.8 billion acquisition of AtaiBeckley at a 26% premium, deepening its neuroscience pipeline in psychedelic-based treatments. The deal explicitly referenced Definium Therapeutics as a peer developing a promising LSD-based approach for MDD, further validating the therapeutic space and investor interest in the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Definium Therapeutics Rises 5.5% in Regular Trading, DT120 Phase 3 Data and Sector M&A Fuel Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Definium Therapeutics Rises 5.5% in Regular Trading, DT120 Phase 3 Data and Sector M&A Fuel Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, Definium Therapeutics rose 5.5% in regular trading, trading at $46.5/share, with turnover of $24.58 million.</p><p>On the news front, multiple catalysts continue to support buying momentum. The company previously reported positive topline results from its pivotal Phase 3 EMERGE study of DT120 oral disintegrating tablet for Major Depressive Disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful improvement over placebo. The company subsequently completed an $805 million capital raise with underwriters fully exercising the overallotment option. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.</p><p>Adding sector tailwinds, Eli Lilly announced a $3.8 billion acquisition of AtaiBeckley at a 26% premium, deepening its neuroscience pipeline in psychedelic-based treatments. The deal explicitly referenced Definium Therapeutics as a peer developing a promising LSD-based approach for MDD, further validating the therapeutic space and investor interest in the stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DFTX","symbol_name":"Definium Therapeutics","start_time":0,"source_url":"","article_id":"1173601696","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173601696","pubTimestamp":1784209420,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, Definium Therapeutics rose 5.5% in regular trading, trading at $46.5/share, with turnover of $24.58 million.On the news front, multiple catalysts continue to support buying momentum. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DFTX":"Definium Therapeutics"},"translate_title":"走势警报|Definium Therapeutics 常规交易上涨 5.5%，DT120 第三阶段数据和行业并购推动动力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DFTX":1},"content_text":"On July 16, Definium Therapeutics rose 5.5% in regular trading, trading at $46.5/share, with turnover of $24.58 million.On the news front, multiple catalysts continue to support buying momentum. The company previously reported positive topline results from its pivotal Phase 3 EMERGE study of DT120 oral disintegrating tablet for Major Depressive Disorder, meeting the primary endpoint and all key secondary efficacy endpoints with statistically significant and clinically meaningful improvement over placebo. The company subsequently completed an $805 million capital raise with underwriters fully exercising the overallotment option. RBC Capital raised its price target from $36 to $57, maintaining an Outperform rating.Adding sector tailwinds, Eli Lilly announced a $3.8 billion acquisition of AtaiBeckley at a 26% premium, deepening its neuroscience pipeline in psychedelic-based treatments. The deal explicitly referenced Definium Therapeutics as a peer developing a promising LSD-based approach for MDD, further validating the therapeutic space and investor interest in the stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173601696","isCrawlerRequest":true}